2019년 2월 8일 금요일
[CK] Colitis ischemic.
https://www.uptodate.com/contents/colonic-ischemia?search=ischemic%20colitis%20treatment&source=search_result&selectedTitle=1~131&usage_type=default&display_rank=1#H26
2019년 2월 6일 수요일
[CK] CMV viremia vs leukopenia.
- Continue medication management for CMV/HSV viremia
-May Consider repeat CMV Ig 10g infusion after Tylenol/Benadryl pretreatment
-Continue Ganciclovir 550mg IV q 12hrs
-Plan to transition to oral Valganciclovir 900mg twice daily at discharge
-May Consider repeat CMV Ig 10g infusion after Tylenol/Benadryl pretreatment
-Continue Ganciclovir 550mg IV q 12hrs
-Plan to transition to oral Valganciclovir 900mg twice daily at discharge
2019년 2월 5일 화요일
[CK] Fluid post CATH. pre 12hours and post 12hours (1cc/kg/hr)
Outpatients ─ We give 3 mL/kg over one hour preprocedure and 1 to 1.5 mL/kg/hour during and for four to six hours postprocedure, with administration of at least 6 mL/kg postprocedure.
●Inpatients ─ We give 1 mL/kg/hour for 6 to 12 hours preprocedure, intraprocedure, and for 6 to 12 hours postprocedure.
2019년 2월 4일 월요일
[CK] Leukopenia - Need to learn more !!! Drug ?!
1. Hold cellcept due to leukopenia
2. Hold ganciclovir due to leukopenia
2. Hold ganciclovir due to leukopenia
2019년 2월 3일 일요일
[CK] PVCs
https://www.uptodate.com/contents/ventricular-premature-beats?search=frequent%20pvc§ionRank=1&usage_type=default&anchor=H15572590&source=machineLearning&selectedTitle=1~150&display_rank=1#H15572590
no clear evidence that VPB suppression with beta blockers or antiarrhythmic drugs improves overall survival in patients who have no symptoms and have not had a major arrhythmic event. Thus, the only indications for the use of beta blockers or antiarrhythmic drugs for VPB suppression are for symptomatic patients or for patients with cardiomyopathy felt to be possibly related to frequent VPBs. Before embarking on drug therapy, however, abstinence should first be advised to an individual with exposure to known stimulants, although this strategy has not been a consistently effective intervention [39]. If VPBs and symptoms persist following abstinence, in the case of absent underlying structural heart disease, offering reassurance to the individual regarding the benign nature of ventricular ectopy may suffice; if not, the next step may be treatment with a beta-blocker and/or a calcium channel blocker. The use of membrane active antiarrhythmic therapy and catheter ablation is reserved for patients who do not respond to treatment with beta blockers or calcium channel blockers, and/or are intolerant or prefer not to take these medications.
no clear evidence that VPB suppression with beta blockers or antiarrhythmic drugs improves overall survival in patients who have no symptoms and have not had a major arrhythmic event. Thus, the only indications for the use of beta blockers or antiarrhythmic drugs for VPB suppression are for symptomatic patients or for patients with cardiomyopathy felt to be possibly related to frequent VPBs. Before embarking on drug therapy, however, abstinence should first be advised to an individual with exposure to known stimulants, although this strategy has not been a consistently effective intervention [39]. If VPBs and symptoms persist following abstinence, in the case of absent underlying structural heart disease, offering reassurance to the individual regarding the benign nature of ventricular ectopy may suffice; if not, the next step may be treatment with a beta-blocker and/or a calcium channel blocker. The use of membrane active antiarrhythmic therapy and catheter ablation is reserved for patients who do not respond to treatment with beta blockers or calcium channel blockers, and/or are intolerant or prefer not to take these medications.
2019년 2월 2일 토요일
피드 구독하기:
글 (Atom)